In conclusion, we demonstrate that ASOs targeting CD39 are able to achieve potent target suppression in relevant cell types in vitro and in vivo and induce potent anti-tumor effects in combination therapy with immune checkpoint inhibitors. Here, ENTPD1 is linked to neoplasm.